 |
|
Randomized Controlled Study of an Intravitreous Dexamethasone Drug Delivery System in Patients With Persistent Macular Edema
Baruch D. Kuppermann, MD, PhD;
Mark S. Blumenkranz, MD;
Julia A. Haller, MD;
George A. Williams, MD;
David V. Weinberg, MD;
Connie Chou, PhD;
Scott M. Whitcup, MD; for the Dexamethasone DDS Phase II Study Group
Arch Ophthalmol. 2007;125(3):309-317.
Objective To evaluate a dexamethasone intravitreous drug delivery system (DDS) in patients with persistent ( 90 days despite treatment) macular edema.
Methods This 6-month study randomized 315 patients with persistent macular edema with best-corrected visual acuity (BCVA) of 20/40 to 20/200 in the study eye to observation or a single treatment with dexamethasone DDS, 350 or 700 µg.
Main Outcome Measures Proportion of patients achieving a BCVA improvement of 10 or more letters or 15 or more letters, safety measures, change in fluorescein angiographic leakage, and central retinal thickness.
Results At day 90 (primary end point), an improvement in BCVA of 10 letters or more was achieved by a greater proportion of patients treated with dexamethasone DDS, 700 µg (35%) or 350 µg (24%), than observed patients (13%; P<.001 vs 700-µg group; P = .04 vs 350-µg group); an improvement in BCVA of 15 letters or more was achieved in 18% of patients treated with dexamethasone DDS, 700 µg, vs 6% of observed patients (P = .006). Results were similar in patients with diabetic retinopathy, vein occlusion, or uveitis or Irvine-Gass syndrome. During 3 months of observation, 11% of treated patients and 2% of observed patients had intraocular pressure increases of 10 mm Hg or higher.
Conclusion In persistent macular edema, a single dexamethasone DDS treatment produced statistically significant BCVA improvements 90 days after treatment and was well tolerated for 180 days.
Application to Clinical Practice Dexamethasone DDS, 700 µg, may have potential as a treatment for persistent macular edema.
Trial Registration clinicaltrials.gov Identifier: NCT00035906
Author Affiliations: Departments of Ophthalmology, University of California, Irvine (Dr Kuppermann), Stanford University, Stanford, Calif (Dr Blumenkranz), and Wilmer Eye Institute, Johns Hopkins University, Baltimore, Md (Dr Haller); Associated Retinal Consultants, Beaumont Eye Institute, Royal Oak, Mich (Dr Williams); The Eye Institute, Medical College of Wisconsin, Milwaukee (Dr Weinberg); and Allergan Inc, Irvine (Drs Chou and Whitcup).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Dexamethasone Inhibits High Glucose-, TNF-{alpha}-, and IL-1{beta}-Induced Secretion of Inflammatory and Angiogenic Mediators from Retinal Microvascular Pericytes
Nehme and Edelman
IOVS 2008;49:2030-2038.
ABSTRACT
| FULL TEXT
Safety Evaluation of Ocular Drug Delivery Formulations: Techniques and Practical Considerations
Short
Toxicol Pathol 2008;36:49-62.
ABSTRACT
| FULL TEXT
From the Library
Br. J. Ophthalmol. 2007;91:846-846.
FULL TEXT
|
